Medicine Online
Any medical inquiries? Search MOL for answers:
NEWS
Home > News > 2005 > February > 4 > Japan OKs Enbrel For Rheumatoid Arthritis
Medical References
Diseases & Conditions
Women's Health
Mental Health
Men's Health
Healthy Choice News
Site Map Links
Medical Tips
Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that may be programmed into our metabolic systems.
Read more health news

Japan OKs Enbrel For Rheumatoid Arthritis

FRIDAY, Feb. 4 (HealthDayNews) -- The drug Enbrel (etanercept) has been by approved for use in Japan to treat people with rheumatoid arthritis (RA) who''ve had an inadequate response to existing therapies.

Enbrel binds to cytokine TNF, an inflammatory compound that plays an important role in the inflammatory process of RA. Binding with the drug renders this cytokine biologically inactive, resulting in significant reductions in inflammatory activity, according to a joint statement from drug companies Wyeth K.K. and Takeda Pharmaceutical Co. Ltd.

The drug is the only fully human, anti-TNF receptor approved to reduce RA signs and symptoms in patients unresponsive to other therapies. It''s administered twice weekly by injection. At first, Enbrel will be made available to medical institutions in Japan taking part in a patient surveillance program.

More than 700,000 Japanese are estimated to suffer from RA, according to the Japanese Medical Association.

More information

The Arthritis Foundation has more about rheumatoid arthritis.



-- Robert Preidt



SOURCE: JCN Newswire news release, Jan. 27, 2005

Last Updated: Feb-04-2005
HomeSitemap Contact UsAdvertisingPress RoomGive Us Your FeedbackRead Our Terms & Conditions and Our DisclaimerPrivacy Statement